Biotech and Pharma Industry News | BioPharma Dive
WEBCell and gene therapy investment, once booming, is now in a slump. Far fewer venture funding rounds were closed by cell and gene therapy developers over the first six months of 2024 than in prior years. Experts say there are several factors. BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives.
Lilly, Boehringer diabetes pill wins expanded use in heart failure
WEBFeb 25, 2022 · The Food and Drug Administration approved expanded use of Eli Lilly and Boehringer Ingleheim’s diabetes drug Jardiance, announcing Thursday that the pill can be used in a broader group of heart failure patients. The FDA cleared the drug for sicker patients, those with weaker heart muscles, in August 2021. The …
Lilly gene therapy finding puts focus on hearing loss treatment ...
WEBJan 24, 2024 · An 11-year-old boy who was born deaf can hear after receiving an experimental gene therapy, developer Eli Lilly reported on Tuesday.. The boy, identified as Aissam Dam by The New York Times, was the first participant treated in a small study Lilly is running to test the therapy, which is designed …
Biotech M&A is on the upswing. Here are the latest deals.
WEBAug 13, 2024 · BioPharma Dive is tracking M&A activity below. The database, which shows drugmaker buyouts that have happened since 2018 and were valued at $50 million or more in upfront consideration, will be regularly updated. Click on an acquiring company to pull up more information, and scroll to the bottom of the page to read how this information was ...
Meso Scale Discovery (MSD): An immunoassay platform with …
WEBFeb 22, 2022 · ADVANTAGES. Sensitivity, Range and Ease-of-Use: In comparison to a conventional ELISA, MSD has higher sensitivity (LLOD 0.1-1.4 pg/mL) and a larger dynamic detection range (0.1-10 pg/mL).In addition, MSD has an efficient low volume sampling (1-25 μ L) and minimized matrix effect aiding in simultaneous multiplex detection with high precision. . Furthermore, MSD has simpler protocols, reduced ...
Shire deal done, Takeda turns to task of forging top pharma
WEBJan 9, 2019 · Shire deal done, Takeda turns to task of forging top pharma. SAN FRANCISCO — Several years ago, executives at Takeda concluded the 237-year-old pharmaceutical firm’s pipeline of experimental drugs was lacking. “We just were not competitive,” Andy Plump, the Japanese drugmaker’s head of research and development, said in an interview.
Lilly reports strong results for next-generation diabetes drug
WEBDec 9, 2020 · Dive Brief: Eli Lilly on Wednesday said its experimental diabetes drug tirzepatide succeeded in its first Phase 3 trial, reporting results showing treatment significantly lowered blood sugar levels in study participants. More than one in five people given a high dose of the drug, however, quit treatment in the trial, called SURPASS-1.
Lilly wins FDA approval for new kind of diabetes drug
WEBMay 13, 2022 · The Food and Drug Administration on Friday approved Eli Lilly’s diabetes drug Mounjaro, a first-of-its-kind treatment that can help control patients’ blood sugar and, potentially, help them lose weight as well. Mounjaro, also known as tirzepatide, expands Lilly’s diabetes business, which includes insulins as well as other types of therapies.
The next era of Greater Boston’s biotech boom | BioPharma Dive
WEBNov 22, 2022 · The next era of Greater Boston’s biotech boom. Over the past two decades, the Cambridge area has become a nerve center for biotech in the U.S. But to stay relevant and accessible, the hub is expanding to the suburbs. Published November 22, 2022 • By Karissa Waddick , Shaun Lucas and Julia Himmel. A map of the Kendall Square neighborhood in ...
Biotech IPOs are the industry’s lifeblood. Track how they’re …
WEB4 days ago · IPO activity reached a peak in 2021, when more than 100 biotechs priced an initial offering and together raised nearly $15 billion. But that momentum came to a halt as 2021 turned to 2022, and stock prices of newly public companies plummeted amid a sector-wide downturn. The pace of IPOs stalled and, last year, only 19 drugmakers priced initial ...
Skip to content